Abstract Ref Number = APCP931
Survival Rate of Pediatric Ewing Sarcoma A Single-Center Retrospective Study for Two Decades
Jennie Sutantio,Riski Muhaimin,Teny Tjitra Sari
RSCM Department of Child Health, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
Background : Ewing sarcoma is the second most common primary bone malignancy in pediatric patients, yet the prognosis is varied among tertiary care centers. We aim to determine survival rate of pediatric patients with Ewing Sarcoma treated in Cipto Mangunkusumo Hospital.
Material : A retrospective study of 33 pediatric patients with Ewing Sarcoma <19 years old diagnosed between 1997-2016 was perfomed. The Kaplan-Meier survival analysis was used to assess overall survival (OS).
Results : The median age at diagnosis was 9 years. Most patients were in age group 5-9 years old (36.4%), followed by 10-14 years old (33.3%), and males were more often affected than females (63.6% vs 36.4%). The most common primary tumor locations were humerus (11.1%), scapula (11.1%), and abdomen (11.1%). Most patients came in stage IV (30.6%), followed by stage II (22.2%). More than half received chemotherapy alone (60.6%), followed by combination of chemotherapy and surgical modalities (24.2%). The median follow-up period was 9 months, and the maximum period was 38 months. The overall survival rate of the first, second, and third year after diagnosis were 66.7%, 50%, and 20%, respectively. Although not statistically significant, patients of age group 15-19 years old had the shortest survival time compared to other groups.
Conclusions : Ewing sarcoma patients had poor treatment outcomes in Cipto Mangunkusumo hospital. Advanced staging at diagnosis, and poor treatment compliance are the most common contributing factors. Further study need to be done to validates factors contributing to the prognosis.
Keywords: survival rate Ewing sarcoma pediatric